德琪医药双抗新药授权优时比3月4日,德琪医药与优时比(UCB)联合宣布,双方已签署协议,德琪医药将授予优时比在全球范围内推进CD19/CD3双特异性T细胞连接抗体ATG-201的开发、生产及商业化的独家权益,包括与ATG-201相关的生产技术授权。据悉,清除B细胞的T细胞衔接器(简称“TCE”)是一类通过选择性清除B细胞来发挥作用的治疗药物,可用于治疗包括自身免疫性疾病及部分血液系统肿瘤在内的多种...
Source Link德琪医药双抗新药授权优时比3月4日,德琪医药与优时比(UCB)联合宣布,双方已签署协议,德琪医药将授予优时比在全球范围内推进CD19/CD3双特异性T细胞连接抗体ATG-201的开发、生产及商业化的独家权益,包括与ATG-201相关的生产技术授权。据悉,清除B细胞的T细胞衔接器(简称“TCE”)是一类通过选择性清除B细胞来发挥作用的治疗药物,可用于治疗包括自身免疫性疾病及部分血液系统肿瘤在内的多种...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.